Exelixis (EXEL) Tops Q3 EPS by 5c, Revenue Misses, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 2, 2021 4:05 PM EDT
- Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Million -
- GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.20 -
- Conference Call and Webcast Today at 5:00 PM Eastern Time -
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Exelixis continued to execute across all facets of our business in the third... More
